TITLE

A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia

AUTHOR(S)
Wang, Shujie; Yang, Renchi; Zou, Ping; Hou, Ming; Wu, Depei; Shen, Zhixiang; Lu, Xijing; Li, Yan; Chen, Xiequn; Niu, Ting; Sun, Hui; Yu, Li; Wang, Zhao; Zhang, Yin; Chang, Naibai; Zhang, Gaokui; Zhao, Yongqiang
PUB. DATE
August 2012
SOURCE
International Journal of Hematology;Aug2012, Vol. 96 Issue 2, p222
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
79193731

 

Related Articles

  • Evaluating the safety and efficacy of recombinant human thrombopoietin among severe sepsis patients with thrombocytopenia: study protocol for a randomized controlled trial. Qin Wu; Jianan Ren; Gefei Wang; Guosheng Gu; Dong Hu; Song Liu; Gunawei Li; Jun Chen; Ranran Li; Zhiwu Hong; Huajian Ren; Xiuwen Wu; Yuan Li; Min Yao; Yunzhao Zhao; Jieshou Li // Trials;2015, Vol. 16 Issue 1, p1 

    Background: Sepsis is still a major health problem that causes high mortality in all populations. Organ dysfunction including sepsis-associated thrombocytopenia is prevalent among sepsis patients, resulting in increasing mortality rates. Considering the clinical role of platelets,...

  • Thrombopoietin-Receptor Agonists for Primary Immune Thrombocytopenia. Imbach, Paul; Crowther, Mark // New England Journal of Medicine;8/25/2011, Vol. 365 Issue 8, p734 

    The article discusses the use of thrombopoietin-receptor agonists for the treatment of primary immune thrombocytopenia. Immune thrombocytopenia is a condition which involves immune-mediated destruction of the platelets and impairment in the production of platelets. The levels of thrombopoietin...

  • Eltrombopag: A Review of its Use in Treatment-Refractory Chronic Primary Immune Thrombocytopenia. Garnock-Jones, Karly P. // Drugs;2011, Vol. 71 Issue 10, p1333 

    Eltrombopag (Revolade®) is an orally bioavailable, low molecular weight, synthetic nonpeptide thrombopoietin receptor agonist, which selectively binds to the transmembrane and juxtamembrane domains of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte...

  • Spotlight on Eltrombopag in Treatment-Refractory Chronic Primary Immune Thrombocytopenia. Garnock-Jones, Karly P. // BioDrugs;2011, Vol. 25 Issue 6, p401 

    Eltrombopag (Revolade is an orally bioavailable, low molecular weight, synthetic nonpeptide thrombopoietin receptor agonist, which selectively binds to the transmembrane and juxtamembrane domains of the thrombopoietin receptor on the surface of platelets, megakaryocytes, and megakaryocyte...

  • Romiplostim: A Review of its Use in Immune Thrombocytopenia. Keating, Gillian M. // Drugs;2012, Vol. 72 Issue 3, p415 

    Romiplostim (Nplate®) is an Fc-peptide fusion protein (peptibody) that acts as a thrombopoietin receptor agonist; it has no amino acid sequence homology with endogenous thrombopoietin. This article reviews the clinical efficacy and toler-ability of subcutaneous romiplostim in adults with...

  • Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia— a randomized, placebo-controlled, double-blind safety and efficacy study Geissler, K.; Liu Yin, J. A.; Ganser, A.; Sanz, M. A.; Szer, J.; Raghavachar, A.; Hoelzer, D.; Martinez, C.; Taylor, K.; Kanz, L.; To, L. B.; Archimbaud, E. // Annals of Hematology;Nov2003, Vol. 82 Issue 11, p677 

    Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) administered after acute myeloid leukemia (AML) chemotherapy (CT) failed to shorten the time of transfusion-dependent thrombocytopenia in a previous study. In this multicenter, randomized, placebo-controlled,...

  • Romiplostim.  // Reactions Weekly;10/12/2013, Issue 1473, p34 

    An abstract of the article "Progression of bone marrow fibrosis with reticulin and collagen hyperplasia during treatment with the thrombopoietin receptor agaonist romiplostim in a patient with immune thrombocytopenia," by K. Kirito and colleagues is presented.

  • Romiplostim resistance in secondary failure of platelet recovery. DeRemer, David L; Katsanevas, Katerina; Bradley, Amber; Awan, Farrukh T // Journal of Oncology Pharmacy Practice;Dec2013, Vol. 19 Issue 4, p369 

    Romiplostim, a thrombopoietin mimetic, is FDA approved for the treatment of thrombocytopenia in patients with refractory immune thrombocytopenia. Given the success of thrombopoietin agonists in the treatment of immune thrombocytopenia, data in other clinical settings are emerging. In the bone...

  • Romiplostim use in ITP. Lohr, Lisa // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p13 

    The article discusses the use of romiplostim in the treatment of immune thrombocytopenia or idiopathic thrombocytopenic purpura (ITP). ITP is a syndrome characterized by accelerated platelet destruction. Romiplostim is a recombinant protein that stimulates platelet production by binding to and...

  • Eltrombopag: A Review of Its Use in the Treatment of Thrombocytopenia in Patients with Chronic Hepatitis C. Burness, Celeste // Drugs;Oct2014, Vol. 74 Issue 16, p1961 

    Eltrombopag (Revolade; Promacta) is an orally bioavailable, small-molecule, thrombopoietin receptor agonist that selectively binds to thrombopoietin receptors on megakaryocyte precursors and megakaryocytes leading to increased platelet production. It is approved in a number of countries for the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics